Login to Your Account

Dimerix's lead compound meets primary endpoints in phase II CKD trial

By Tamra Sami
Staff Writer

Thursday, July 13, 2017

PERTH, Australia – Dimerix Ltd. reported positive phase IIa data with its lead program, DMX-200, in chronic kidney disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription